ReviewInternational journal of pharmaceutics: X2026
3D-printed polypills for personalized medicine and precision oral drug delivery in pharmaceutical practice: A review.
Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Digital Design to Dosage Performance: Material-Process-Geometry Interactions in 3D-Printed Oral Tablets.AAPS PharmSciTech · 2026Review
- Three-Dimensional Bioprinting and Rose-Inspired Medical Applications.Biomimetics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D-printed polypills have considerably changed the way oral medications can be delivered. They offer a way to create a single dosage form that can be customized to meet the needs of individual patients, while also allowing multiple drugs to be stored in distinct compartments, layers, or designs. Using 3D printing techniques such as fused deposition modeling (FDM), inkjet printing, stereolithography (SLA), selective laser sintering (SLS), and Arburg Plastic Freeforming (APF), it is possible to create tablet structures that provide control over various aspects of dissolution and drug release through engineered porosity and density of the material used during fabrication. Several technologies have been developed to enable the fabrication of polypills, along with methods for selecting the correct excipients, controlling drug release through various mechanisms, and considering the principles of quality-by-design when creating a polypill. In recent years, new material innovations have significantly enhanced the ability of polypills to deliver drugs with improved mechanical strength, stability, and accuracy upon printing. The ability to provide personalized medication regimens for patients with chronic diseases requiring precise titration or a complex regimen is expected to have a great impact on the management of patients taking 3D-printed polypills. 3D-printed polypills have significant translational challenges due to inconsistent production, difficulty obtaining regulatory approval, the inability to scale up batch manufacture, and inadequate long-term stability of the final product.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.